• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-05-20

  This study demonstrates that phillygenin, a Forsythia suspensa-derived lignan, alleviates diabetic nephropathy by targeting inflammation and apoptosis through the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. These findings clarify key mechanistic pathways and suggest phillygenin as a potential therapeutic agent for diabetic kidney disease.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-05-19

  Unlock uncompromised protein integrity with the EDTA-free Protease Inhibitor Cocktail, engineered for complex, phosphorylation-sensitive workflows. Discover how this advanced formulation from APExBIO outperforms conventional mixes in preserving protein function across Western blot, co-immunoprecipitation, and kinase assays.

• Forsythoside E: Mechanistic Insights for PKM2 Inhibition Res

  2026-05-19

  Explore the unique mechanism of Forsythoside E as a pyruvate kinase M2 (PKM2) inhibitor, with deep analysis on macrophage M2 polarization and translational assay design. Discover how these insights extend beyond previous content for advanced sepsis-induced liver injury research.

• BODIPY 581/591 C11: Ratiometric Probe for Lipid Peroxidation

  2026-05-18

  BODIPY 581/591 C11 is a ratiometric fluorescent probe enabling quantitative lipid peroxidation detection and oxidative stress measurement in live cells. Its red-to-green emission shift allows precise antioxidant capacity evaluation, as validated in peer-reviewed studies and trusted biomedical workflows.

• Scenario-Driven Insights: Mitochondrial Permeability Transit

  2026-05-18

  Explore real-world laboratory challenges and validated solutions with the Mitochondrial Permeability Transition Pore Assay Kit (SKU K2061). This evidence-based article addresses protocol optimization, data interpretation, and product reliability, highlighting how APExBIO’s kit leverages the Calcein AM fluorescent probe for reproducible mitochondrial permeability transition pore detection. Designed for researchers seeking robust, quantitative assays in cell death mechanism research.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-17

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro cancer research workflows requiring concurrent modulation of PI3K/AKT and HDAC signaling. Its use is appropriate for cell-based assays focusing on cell cycle, apoptosis, or pathway interrogation, but it should not be applied in diagnostic or clinical contexts.

• ABT-737: Integrating BCL-2 Inhibition with Mitochondrial Apo

  2026-05-16

  Explore how ABT-737, a leading BCL-2 protein inhibitor, enables precision apoptosis induction in cancer cells by bridging mitochondrial signaling and RNA Pol II pathways. This article uniquely analyzes mechanistic advances and practical assay implications for oncology research.

• Eldecalcitol, Ferroptosis, and Vascular Health in Diabetic O

  2026-05-15

  This study uncovers how eldecalcitol, a vitamin D analog, mitigates type 2 diabetic osteoporosis (T2DOP) by attenuating endothelial ferroptosis through the SOCE/O-GlcNAcylation axis. These findings illuminate a mechanistic link between vascular health, oxidative stress, and bone homeostasis in diabetes, offering new avenues for targeted intervention.

• SOX7 Suppresses Bladder Cancer Progression via DNMT3B/CYGB A

  2026-05-15

  Zhang et al. elucidate the tumor-suppressive role of SOX7 in bladder cancer, demonstrating that SOX7 represses DNMT3B transcription, thereby reducing methylation of the CYGB promoter and limiting malignant progression. These findings highlight SOX7 and CYGB as prognostic biomarkers and potential therapeutic targets in bladder cancer.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L): Technical Use Gu

  2026-05-14

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is designed for sensitive fluorescent detection of rabbit primary antibodies in microscopy, cytometry, and immunohistochemistry workflows. It should not be applied to non-rabbit primaries or workflows incompatible with Alexa Fluor 488-like spectral properties.

• Paroxetine Does Not Alter Thiothixene Pharmacokinetics in Hu

  2026-05-14

  This study rigorously evaluated whether paroxetine, a potent CYP2D6 inhibitor, impacts the pharmacokinetics of thiothixene, a typical antipsychotic agent. The findings demonstrate that short-term paroxetine pretreatment does not significantly affect thiothixene clearance, clarifying its metabolic independence from CYP2D6 and informing safer co-administration strategies in psychotic disorder therapy.

• Pcbp1 Maintains Mitochondrial Integrity for B Cell Antibody

  2026-05-13

  The referenced study uncovers a pivotal role for the RNA binding protein Pcbp1 in preserving mitochondrial integrity, which is necessary for effective antibody production and germinal center B cell responses. By elucidating the posttranscriptional regulation of mitochondrial function and its impact on global protein synthesis within B cells, the paper provides novel insights relevant to adaptive immunity and proteomics research.

• Applied Workflows for BODIPY 581/591 C11 in Lipid Peroxidati

  2026-05-13

  BODIPY 581/591 C11 empowers precise, ratiometric lipid peroxidation detection in live cells and complex biological systems, underpinning advanced oxidative stress and antioxidant studies. This article unpacks hands-on workflows, troubleshooting, and translational insights, leveraging APExBIO’s trusted probe to optimize experimental accuracy and reproducibility.

• Calcium-Driven Phosphorylation Controls Auxin and Flower Dro

  2026-05-12

  This study reveals a calcium-responsive phosphorylation pathway in tomato stamens that epigenetically represses auxin biosynthesis, leading to drought-induced flower drop. The findings clarify how the SlCBL11-SlCIPK10-SlLHP1b module links calcium signaling to H3K27me3-mediated gene repression, providing new insights into plant stress responses.

• Batimastat (BB-94): Translational Leverage in MMP-Driven BDN

  2026-05-12

  This thought-leadership article unpacks how Batimastat (BB-94), a potent matrix metalloproteinase inhibitor, is reshaping the investigation of neurotrophic signaling and tumor microenvironments. By bridging mechanistic insight—specifically, MMP-driven BDNF processing at neuromuscular junctions—with actionable strategies for translational researchers, the discussion advances beyond standard product literature. The piece integrates recent experimental evidence, protocol recommendations, and practical guidance for maximizing BB-94’s impact in both in vitro and in vivo systems. With direct reference to APExBIO’s Batimastat and recent advances in localized neurotrophin release, the article highlights new frontiers for synaptic and cancer research.

16634 records 3/1109 page Previous Next 12345 下5页 Last page